Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Hexal: Generic Consolidation, and More

Executive Summary

Buying Hexal shows Novartis' commitment to generics. The Swiss group also hopes the move will bring more credibility, and better deals, across all of its businesses.
Advertisement

Related Content

Not-For-Profit Makes Business Sense, Too
How Biopharma Can Flourish in a Deteriorating Environment
Novartis Buys into New Pharma World Order
Teva/Ivax: Generics' Answer to Big Pharma
Deal Statistics Quarterly, Q1 2005
Indian Generics: Growing in Europe
German Health Care Reform: Raising the Innovation Threshold
Authorized Generics: Band-Aid or Strategy?
FDA Hesitates on Biogenerics
Savoring Sabex: Sandoz' Play in Injectable Generics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002548

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel